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BEST1 Gene Therapy Corrects a Diffuse Retina-Wide Microdetachment
Modulated by Light Exposure
Abstract
Mutations in the BEST1 gene cause detachment of the retina and degeneration of photoreceptor (PR) cells
due to a primary channelopathy in the neighboring retinal pigment epithelium (RPE) cells. The
pathophysiology of the interaction between RPE and PR cells preceding the formation of retinal detachment
remains not well-understood. Our studies of molecular pathology in the canine BEST1 disease model revealed
retina-wide abnormalities at the RPE-PR interface associated with defects in the RPE microvillar
ensheathment and a cone PR-associated insoluble interphotoreceptor matrix. In vivo imaging demonstrated a
retina-wide RPE-PR microdetachment, which contracted with dark adaptation and expanded upon exposure
to a moderate intensity of light. Subretinal BEST1 gene augmentation therapy using adeno-associated virus 2
reversed not only clinically detectable subretinal lesions but also the diffuse microdetachments.
Immunohistochemical analyses showed correction of the structural alterations at the RPE-PR interface in
areas with BEST1 transgene expression. Successful treatment effects were demonstrated in three different
canine BEST1 genotypes with vector titers in the 0.1-to-5E11 vector genomes per mL range. Patients with
biallelic BEST1 mutations exhibited large regions of retinal lamination defects, severe PR sensitivity loss, and
slowing of the retinoid cycle. Human translation of canine BEST1 gene therapy success in reversal of macro-
and microdetachments through restoration of cytoarchitecture at the RPE-PR interface has promise to result
in improved visual function and prevent disease progression in patients affected with bestrophinopathies.
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Mutations in the BEST1 gene cause detachment of the retina and de-
generation of photoreceptor (PR) cells due to a primary channelopathy
in the neighboring retinal pigment epithelium (RPE) cells. The patho-
physiology of the interaction between RPE and PR cells preceding the
formation of retinal detachment remains not well-understood. Our
studies of molecular pathology in the canine BEST1 disease model
revealed retina-wide abnormalities at the RPE-PR interface associ-
ated with defects in the RPE microvillar ensheathment and a cone
PR-associated insoluble interphotoreceptor matrix. In vivo imaging
demonstrated a retina-wide RPE–PR microdetachment, which con-
tracted with dark adaptation and expanded upon exposure to a
moderate intensity of light. Subretinal BEST1 gene augmentation
therapy using adeno-associated virus 2 reversed not only clinically
detectable subretinal lesions but also the diffuse microdetachments.
Immunohistochemical analyses showed correction of the structural
alterations at the RPE–PR interface in areas with BEST1 transgene
expression. Successful treatment effects were demonstrated in
three different canine BEST1 genotypes with vector titers in the
0.1-to-5E11 vector genomes per mL range. Patients with biallelic
BEST1 mutations exhibited large regions of retinal lamination de-
fects, severe PR sensitivity loss, and slowing of the retinoid cycle.
Human translation of canine BEST1 gene therapy success in reversal of
macro- and microdetachments through restoration of cytoarchitecture
at the RPE–PR interface has promise to result in improved visual
function and prevent disease progression in patients affected with
bestrophinopathies.
bestrophinopathy | AAV BEST1 gene therapy | RPE | microvilli |
photoreceptors
Inherited retinal degenerations (IRDs) encompass a largegroup of blinding conditions that are molecularly heteroge-
neous and pathophysiologically distinct (1, 2). The genetic defect
often acts primarily on rod or cone photoreceptors (PRs), or
both, and the specific defect may involve phototransduction,
ciliary transport, morphogenesis, neurotransmission, or others.
Less common are primary defects involving the retinal pigment
epithelium (RPE), although they have received increased at-
tention due to high-profile clinical trials (3–5).
The most common IRD due to a primary RPE defect is caused
by mutations in BEST1 (6–8), encoding a transmembrane pro-
tein associated with the basolateral portion of the RPE (9–11).
BEST1 acts as a multifunctional channel protein responsible for
mediating transepithelial ion transport, regulation of in-
tracellular calcium signaling and RPE cell volume, and modu-
lation of the homeostatic milieu in the subretinal space (10–17).
Additional insights supporting BEST1 function as a calcium-
modulated anion channel came from recent crystallographic
studies, which revealed a similar structural architecture between
avian (18) and bacterial (19) homologs. In eukaryotic cells,
BEST1 forms a stable homopentamer with four transmembrane
helices, cytosolic N and C termini, and a continuous central pore
sensitive to calcium-dependent control of chloride permeation
(18). Further analysis of BEST1 structure with targeted muta-
tions has begun to uncover the specific mechanisms responsible
for ion selectivity and calcium-mediated activation of this chan-
nel protein (20).
In humans, BEST1 mutations result in a wide spectrum of
IRDs collectively grouped as bestrophinopathies that often in-
volve pathognomonic macular lesions (6, 7, 21). Retinal regions
away from the lesions tend to appear grossly normal, despite
the existence of a retina-wide electrophysiological defect in the
electrooculogram, which reflects an abnormality in the standing
potential of the eye (21, 22). Naturally occurring biallelic mu-
tations in the canine BEST1 gene (cBEST1) cause canine IRD
with distinct phenotypic similarities to both the dominant and
recessive forms of human bestrophinopathies, including the
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salient predilection of subretinal lesions to the canine fovea-like
area (17, 23, 24).
Proper anatomical apposition and a sustained interaction be-
tween RPE apical microvilli (MV) and PR outer segments (OSs)
are considered crucial for normal vision. Both the ionic com-
position and volume regulation of the subretinal space are es-
sential for maintaining the accurate molecular proximity of this
complex and homeostasis of the RPE–PR interface (25, 26). In
vitro and ex vivo studies have long shown that genetic mutations,
metabolic perturbations, as well as light stimuli alter the ionic
composition of the subretinal space and physiological responses
of the RPE and/or PRs (27–29). More recently, in vivo studies
of outer retinal microanatomy in health and disease and its
response to light have become increasingly informative with
modern retinal imaging modalities (30–40). Here, we combined ex
vivo and in vivo approaches to discover and quantify an abnormal
modulation of the RPE–PR distance by light exposure in canine
bestrophinopathy (cBest). We demonstrate that this is a retina-wide
abnormality, and show that adeno-associated virus (AAV)2-mediated
BEST1 gene augmentation corrects this primary subclinical defect as
well as the disease.
Results
Early Retina-Wide Pathology at the RPE–PR Interface. To understand
the pathophysiology behind the impaired RPE–PR interaction,
we first evaluated cBest retinas with clinically obvious disease.
The key features of RPE apical membrane responsible for direct
interaction with PR OSs were examined by immunohistochem-
istry (IHC) against EZRIN, a membrane–cytoskeleton linker
protein essential for formation of RPE apical MV, and combined
with human cone arrestin (hCAR) and peanut agglutinin lectin
(PNA) labeling to distinguish the cone PR matrix-specific in-
terface (Fig. 1). Confocal microscopy and analysis of 3D re-
construction images from the wild-type (WT) retina exposed a
complex sheet-like structure of both inherent constituents of
RPE apical membrane: cone- and rod-associated MV. Cone-MV
(also known as RPE apical cone sheath) (41) were more pro-
nounced than rod-MV, and formed a highly organized wrapping
that tethered individual cone outer segments (COSs) to the RPE
apical surface (Fig. 1A and Movie S1). In the subretinal space,
this intercellular complex was further encased with an equally
intricate cone-specific insoluble extracellular matrix sheath
(cone-IPM) detected by selective binding of PNA lectin (42)
(Fig. 1A and Movie S1). In diseased cBest retinas, however, such
complex extracellular compartmentalization of COSs was lost,
and the dearth of microvillar ensheathment was accompanied by
hypertrophied RPE cells overloaded with lipofuscin granules and
compromised insoluble cone-IPM (Fig. 1B and Movie S2). These
observations were confirmed in three distinct cBEST1 genotypes
(R25*/R25*, P463fs/P463fs, and R25*/P463fs) examined across
both the tapetal and nontapetal portions of the retina in 22 eyes
after disease onset (age range 45 to 270 wk).
To evaluate the possibility that the structural cone-MV abnor-
malities are secondary to cone dysfunction and disease, we exam-
ined the RPE–COS interaction in a different canine IRD model: a
primary cone photoreceptor channelopathy, CNGB3-associated
achromatopsia (43). We first examined the RPE–COS complex at
6 wk of age; CNGB3-mutant retinas, harboring either a missense or
locus deletion mutation (43), showed no apparent irregularities at
the RPE–PR interface, and the proper localization of RPE apical
markers was associated with specific anti-BEST1 labeling (Fig. S1
A and B). Double immunostaining demonstrated specific distri-
bution of EZRIN along cone-MV interdigitating with hCAR-
positive yet CNGB3-negative COSs (Fig. S1 A and B). Then we
studied the consequences of CNGB3 channel subunit dysfunction
in older (ages 57 and 85 wk) mutant retinas, which undergo a
gradual cone PR degeneration (44), and found that the microvillar
ensheathment of the RPE apical domain still remained largely
intact (Fig. S1 C and D).
The findings in CNGB3-mutant retinas suggested that the
structural alterations associated with cone-MV ensheathment in
cBest were not secondary to a cone defect but specific to the
RPE channelopathy triggered by mutations in BEST1. We then
focused on the 6-wk time point, which is well before clinical
disease onset and near the end of postnatal retinal differentia-
tion in dogs (45) (Fig. 1 C and D). In contrast to the age-matched
WT control, the lack of specific basolateral BEST1 immuno-
labeling in the cBest RPE was associated with a rather smooth
apical surface and clearly underdeveloped (vestigial) apical mi-
crovilli (Fig. 1C, arrowheads). Quantification of the spatial
density of cone-MV and the length of cone- and rod-MV was
performed on deconvolved 3D Z-stack projection images at four
retinal locations (Fig. 1D). Significant differences (P < 0.0001) in
the mean number of cone-MV were found between cBest and
WT in each retinal region examined (Fig. 1D). Even though the
cone photoreceptor numbers were comparable to controls, the
cone-MV in cBest were much fewer in number, sparsely distrib-
uted, and consistently appeared shorter and much finer than those
in controls regardless of the topographical location. In control
(WT) eyes, the average length of cone-MV was 17.4 (±0.25) μm in
the tapetal superotemporal quadrant and 12.3 (±0.23) μm in the
inferior nontapetal retina, whereas the length of rod-MV was 6.7
(±0.11) μm and 5.3 (±0.27) μm in the tapetal and nontapetal
portions of the retina, respectively. In cBest, however, the average
length of rare cone-MV extensions identified was substantially
reduced (6.0 ± 0.31 and 6.5 ± 0.74 μm in the central tapetal and
nontapetal inferior parts, respectively). A quantitative assessment
of the minute rod-MV in cBest was beyond the limits of optical
resolution.
cBEST1-Mutant Eyes Have Retina-Wide Microdetachments That Expand
with Light Exposure. To determine in vivo correlates of the early
RPE–PR interface abnormalities detected by IHC, we used non-
invasive imaging with optical coherence tomography (OCT) to
evaluate cBest eyes at young ages, well before ophthalmoscopic
lesions are detectable. Qualitatively, central retinas of all evalu-
ated eyes showed an additional hyposcattering layer in the outer
retina located distal to the outer nuclear layer (ONL) that was not
detectable in WT eyes (Fig. 2A, arrow and double arrow). Un-
expectedly, the hyposcattering layer was variable with repeated
recordings in the same eye within a single experimental session.
Further analyses uncovered that the width of the hyposcattering
layer was greater in scans obtained toward the end of an imaging
session, when the retina would have been exposed to greater
retinal irradiance due to intervening autofluorescence imaging
performed with bright short-wavelength lights (Fig. 2A, double
arrow, more LA). The width of the hyposcattering layer was less in
scans obtained early in the imaging session before autofluorescence
imaging was performed (Fig. 2A, arrow, less LA).
Quantitative studies were performed by obtaining longitudinal
reflectivity profiles and making measurements both at nasal and
temporal retinal locations. WT eyes (n = 12, ages 15 to 17 wk)
showed outer retinal hyperscattering peaks at the outer plexi-
form layer (OPL) and the external limiting membrane (ELM)
defining the intervening hyposcattering layer as the ONL (Fig.
2B). Distal to the ELM was a hyperscattering peak corre-
sponding to the junction between inner and outer segments of
photoreceptors (IS/OS), a major peak originating near the RPE–
tapetum interface (RPE/T), and an intervening minor hyper-
scattering peak corresponding to photoreceptor OS tips, which
was often difficult to resolve (Fig. 2B). An abnormal hypo-
scattering layer (Fig. 2B, arrows) was detectable in cBest eyes
(n = 6, age 11 wk) with less light exposure. With greater light
exposure, the hyposcattering layer became deeper and more
distinct (Fig. 2B, double arrows); both nasal and temporal retinal
locations showed the same effect. The distance between the
IS/OS and RPE/T peaks (Fig. 2 A and B, arrowheads) was measured.
In WT eyes, the distance was 41.3 (±4.5) μm, whereas in cBest eyes
this distance was significantly greater (P < 0.001) at 46.8 (±6.7) μm
and 45.2 (±6.8) μm (less light exposure) and 55.8 (±10.5) μm and
53.5 (±6.3) μm (more light exposure) for nasal and temporal retinal
regions, respectively (Fig. 2C).
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Two types of experiments were designed to better understand
the thickness of the hyposcattering layer as a function of light
exposure. In the main experiment (WT, n = 12, age 15 to 17 wk;
cBest, n = 3, age 13 wk), eyes were dark-adapted overnight and
then sequential imaging was performed in the dark over a 2-h
period with five intervening brief 488-nm light exposures of in-
crementally greater intensity ranging from very dim lights to
moderate lights produced by standard clinical ophthalmic
equipment (Fig. 2D). In a shorter experimental protocol, only
the highest two light exposures were used in different eyes
(cBest, n = 3, age 13 wk). After overnight dark adaptation, IS/OS–
RPE/T distance was 40.0 (±4.5) μm in WT eyes, whereas it was
47.1 (±4.8) μm in cBest (Fig. 2E); the difference was statistically
significant (P < 0.001). Increasingly brighter light exposures
resulted in monotonic expansion of the IS/OS–RPE/T distance in
cBest eyes, reaching an apparent plateau of 59.4 (±8.7) μm (Fig.
2E). In WT eyes, the effect of the light exposure was either neg-
ligible or small, with the IS/OS–RPE/T distance reaching a plateau
of 40.9 (±4.3) μm. Thus, exposure to light appeared to cause an
acute retinal microdetachment of up to 18.4 (±8.7) μm in cBest
eyes within minutes at an age preceding any detectable ophthal-
moscopic findings. The light-mediated microdetachment dis-
appeared over a time span of less than 24 h (Fig. S2).
In preparation for localized gene therapy, retinotopic distribu-
tion of light-driven microdetachments was evaluated in fully light-
adapted cBest and WT eyes (Fig. 2F). The mean IS/OS–RPE/T
distance across WT eyes (n = 4, age 104 wk) was relatively ho-
mogeneous across superior and inferior retinal areas, with a clear
boundary corresponding to the transition between tapetal and
pigmented (nontapetal) retina. Greater distance in the tapetal
retina of WT eyes was likely due to differences in the dominant
contributors to the hyperscattering peak (tapetum in the tapetal
retina versus pigmented RPE). In a cBest eye (R25*/P463fs) at
age 297 wk, there was a relatively diffuse retina-wide micro-
detachment in addition to grossly obvious retinal detachment at
the fovea-like region (Fig. 2F, demarcated with purple). In a
younger cBest eye (P463fs/P463fs) at age 12 wk, there was a dis-
tinct band of greater microdetachment along the visual streak and
surrounding the optic nerve head even though no ophthalmo-
scopic abnormalities were evident. Difference maps between
mutant eyes and mean WT demonstrated the spatial distribution
of the extent of microdetachments (Fig. 2F, Right).
To assess the potential adverse consequences on photorecep-
tors, ONL thickness was topographically mapped across the retinal
areas with microdetachments (Fig. S3). The microdetachments did
not result in thinning of the ONL that would be expected from
photoreceptor degeneration. Instead, there was a tendency for the
ONL in cBest to be homogeneously thicker than WT; hyperthick
regions typically included the central-superior tapetal retina, but
could also extend into the inferior nontapetal retina (Fig. S3A). Of
importance, the hyperthick regions of the ONL, when examined
microscopically, had numbers of PR nuclei that were comparable
to controls. This suggests an expansion of internuclear spacing as
the likely cause of hyperthick ONL observed by imaging.
Natural History of Canine Bestrophinopathy. As a prerequisite to
assessing gene therapy outcomes, the natural history of cBest was
determined from a group of 18 dogs [12 male (M) and 6 female
Fig. 1. Retina-wide pathology of RPE apical micro-
villar projections associated with BEST1 mutations.
(A and B) Confocal images illustrating the molecular
pathology of cBest (R25*/R25*; 89 wk) (B) compared
with wild-type (A) (42 wk). Retinal cryosections
immunolabeled with anti-EZRIN (green) and human
cone arrestin (red) and combined with peanut ag-
glutinin lectin (cyan) and DAPI (blue) detail the
structural alterations underlying loss of the native
extracellular compartmentalization of cone photo-
receptor outer segments (B). The RPE apical marker,
EZRIN, recognizes both the smaller hair-like projec-
tions capping rod OS tips (rod-MV) as well as the
more complex and substantial cone-associated MV
(cone-MV). The bilayered extracellular ensheath-
ment associated with a single cone OS (COS) is
shown in the magnified photomicrographs (Right),
along with the corresponding schematic representation.
LF, lipofuscin. (Scale bars, 10 μm.) (C) Representative
photomicrographs of 6-wk-old canine wild-type and
cBest-mutant (R25*/P463fs) retinas immunolabeled
with anti-BEST1 (red) and anti-SLC16A1 (green); white
arrowheads point to a subset of cone-MV. H&E, he-
matoxylin & eosin staining; PRL, photoreceptor IS/OS
layer. (Scale bars, 20 μm.) (D) Quantification of cone-MV
numbers across the retina between cBest-mutant and
age-matched control eyes. The y axis represents the
average number of cone-MV per squaremillimeter for
each color-coded retinal region examined (i, inferior;
N, nasal; S, superior; T, temporal) with error bars ± SD
(****P < 0.0001; n = 80 regions of interest per eye).








(F); age range 6 to 297 wk] (Table S1). cBest dogs were serially
monitored by ophthalmoscopy and noninvasive imaging to detect
the onset of earliest disease and understand disease progression.
Based on the systematic in vivo imaging, the first disease signs
were detected as early as 11 wk of age (mean age of 15 wk) as a
subtle focal retinal elevation of the canine fovea-like regions
(Fig. S4A). This discrete RPE–PR detachment on cross-sectional
imaging, yet unnoticeable on en face imaging, was found to be
consistent among cBest eyes examined (n = 34), regardless of
genotype. From the subclinical stage, the disease progressed to
form a macrodetachment (vitelliform stage) limited to the canine
fovea and surrounded by microdetachment (Fig. 3A, Left). The
primary lesion gradually evolved to manifest as a characteristic
bullous detachment within the area centralis that encompassed
the fovea-like region (Fig. 3A, Middle and Right and Fig. S4 B–
D). The presence of distinctive hyperautofluorescence was evi-
dent in the inferior part of the lesion (Fig. 3A, Middle Insets;
pseudohypopyon stage). The advanced disease stages involved a
partial resorption and dispersion of the hyperautofluorescent
material within the central lesion, associated with significant
thinning of ONL (Fig. S4 E and F).
In each case followed by serial imaging (Table S1), cBest
manifested bilaterally and nearly always presented a remarkable
symmetry, albeit with a variable rate of progression (Fig. 3A and
Fig. S4). The gross retinal detachments, ophthalmoscopically
visible in both eyes, either remained limited to the central retina
or became more extensive with extracentral lesions scattered
throughout, still with a strong predilection to the central cone-
rich areas and associated with hyperthick ONL.
Subretinal BEST1 Gene Augmentation Therapy Stably Corrects
Disease. To evaluate proof of concept for AAV2-mediated sub-
retinal gene augmentation therapy, 22 cBest eyes were injected
[vector titers in the 0.1 to 5E11 vector genomes (vg) per mL
range or balanced salt solution (BSS) control] at 27 to 69 wk
(Table S1) with a canine (cBEST1) or human (hBEST1) trans-
gene driven by the human VMD2 promoter (46). cBest dogs
exhibiting different stages of focal or multifocal retinal detach-
ments were either injected unilaterally with AAV leaving the
fellow eye uninjected, or with AAV in one eye and control (BSS)
injection in the contralateral eye; three cases manifesting mul-
tifocal disease were injected bilaterally with AAV targeting the
superotemporal quadrant, while the retinal areas outside of the
surgical bleb served as an internal control (Table S1).
A representative result is shown from a compound heterozy-
gous (R25*/P463fs) dog displaying advanced central retinal de-
tachment in the right eye (EM356-OD) (Fig. 3A) that underwent
subretinal injection with cBEST1 at the age of 52 wk (Fig. 3B,
Left), while the fellow eye was not injected (EM356-OS) (Fig.
S4). Both eyes were monitored clinically and by in vivo imaging.
Disease reversal was first apparent in the injected eye at 4 wk
postinjection (p.i.) and retained a sustained effect long-term, as
illustrated at 43 and 245 wk p.i. (Fig. 3B). In this and other cases
with advanced disease that presented extensive accumulation of
autofluorescent material within the subretinal macrodetach-
ments (n = 13 eyes), hyperautofluorescent signals were still de-
tectable for several months post AAV injection but gradually
faded over time (Fig. 3B, Insets). Based on noninvasive imaging,
both the focal as well as extracentral lesions within the AAV-
BEST1–treated regions resolved 4 to 12 wk p.i., and localized
retinal reattachments remained stable thereafter (Table S1).
There was no evidence of inflammatory responses in any of the
AAV-treated eyes, and the longitudinal in vivo evaluations did
not reveal adverse effects on the RPE or neural retina.
AAV-mediated treatment with the hBEST1 also resulted in
lesion reversal and long-term disease correction (n = 13 eyes).
Representative in vivo imaging results and IHC evaluations (Fig.
3 C and D) from a cBest dog (R25*/R25*) showed that the early
bilateral lesions present before treatment disappeared after the
study eye (EMC3-OS) was treated with AAV-hBEST1 (2E11 vg/mL)
(Fig. 3D), while the lesion in the contralateral control eye
(EMC3-OD) injected with BSS continued to enlarge (Fig. 3C).
Based on funduscopic examination, in the illustrated example as
well as in all other cases the transient retinal detachment associ-
ated with vector or BSS delivery resolved within 24 to 48 h p.i.;
however, the retinal lesions injected with BSS reappeared as early
Fig. 2. Light-mediated changes in the outer retinal structure. (A) Cross-
sectional imaging along the horizontal meridian through the central area
centralis (fovea-like area) in a 15-wk-old normal (WT) dog (Left) and an 11-wk-
old cBest (R25*/P463fs) with less (Middle) and more (Right) light adaptation
(LA). (Insets) En face reflectance images; the thin white arrows show the
superotemporal location of the OCT. The arrowheads and single and double
arrows are described in B. (B) Longitudinal reflectivity profiles (LRPs) (average
of 85 single LRPs) at 3° nasal from the fovea-like area (T, temporal retina) and
nasal edge of the optic nerve head (N, nasal retina) in WT dogs (12 eyes, age
15 to 17 wk) compared with cBest (6 eyes, age 11 wk) with less and more LA.
Arrowheads mark IS/OS and RPE/T peaks; single and double arrows mark the
additional hyporeflective layer in cBest. (C) Distance between IS/OS and RPE/T
peaks in WT and cBest eyes under two LA conditions. Symbols with error bars
represent mean (±2 SD) distance for each group of eyes at both locations.
(D, Upper) Schematic description of the dark and light adaptation protocol.
Animals were dark-adapted (D/A) overnight and OCT imaging was performed.
Then, five increasing light exposures (L1 through L5) were used. Following
each light exposure, OCT imagingwas repeated. (D, Lower) Magnified views of
the OCT scans in cBest with overlapping LRPs after overnight dark adaptation
(Left) and after the maximum light exposure (Right). Arrowheads and single
and double arrows are described in B. (E, Left) Distance between IS/OS and
RPE/T peaks after overnight dark adaptation and following increasing expo-
sures to light (L1 to L5, 488 nm; vertical lines) in cBest (n = 3; colored traces
represent individual eyes) and WT eyes (gray traces). (E, Right) In a different
subset of cBest eyes (n = 3; colored traces), results of using an abbreviated
protocol involving only L4 and L5 exposures. (F) Spatial topography of IS/OS-to-
RPE/T distance in mean WT compared with two representative cBest eyes
[pseudocolor panels; EM356-OS: 297-wk-old cmr1/cmr3 (R25*/P463fs); LH30-
OD: 12-wk-old cmr3 (P463fs/P463fs)]. Purple indicates gross retinal de-
tachment. Grayscale panels show the point-by-point difference between each
cBest eye and the mean WT.
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as 1 wk p.i., and progressed along the natural disease course (Fig.
3C). This was in sharp contrast to the AAV-treated eyes, where
both the early as well as more advanced lesions resolved within the
first 6 wk after hBEST1 gene therapy, and the treated areas
thereafter remained disease-free (Fig. 3D). Ophthalmological ex-
aminations and IHC assessments using RPE- and PR-specific
markers showed no adverse effects on the retina up to 207 wk
p.i. (Fig. 3 and Figs. S5 and S6). Of particular importance, the
assessments of the retinal preservation p.i. revealed a remarkable
restoration of retinal architecture at the RPE–PR interface, in-
cluding extension of cone-MV and actin cytoskeleton rescue,
corresponding to the vector-treated bleb area with either the
canine or human BEST1 transgenes (Fig. 3 C and D, Lower and
Figs. S5 and S6). No differences in the clinical picture or response
to the AAV-BEST1 treatment were observed between genders.
Correction of Light-Modulated Microdetachments with Gene Therapy.
To understand the consequences of BEST1 gene augmentation
therapy on retinal regions without ophthalmoscopically detect-
able retinal detachments, IS/OS–RPE/T distance was measured
topographically within and outside subretinal blebs (Fig. 4). A
representative result with a control subretinal BSS injection at
age 69 wk in a cBest (R25*/P463fs) dog showed homogeneous
microdetachment covering all the imaged retina at age 87 wk (Fig.
4A). The average microdetachment extent (IS/OS–RPE/T dis-
tance of the BSS-injected mutant dog subtracted from colocalized
measurements performed inWT eyes) was 11.6 μm in the superior
retina and 16.7 μm in the inferior retina (Fig. 4B), consistent with
uninjected cBest eyes. Subretinal AAV gene therapy, on the other
hand, resulted in substantial reduction of the IS/OS–RPE/T dis-
tance in treated regions. EMC3-OS, EML4-OS, and LH21-OS
demonstrate results in three genotypes treated with gene ther-
apy using the human BEST1 transgene with titers of ∼2E11 vg/mL
(Fig. 4A and Table S1). In each case, there was significant re-
duction of the IS/OS–RPE/T distance in the treated bleb. Notably,
gross retinal detachments (purple) were only detectable outside
the treatment region (Fig. 4A). Quantitative measurements
showed complete amelioration of the microdetachments, with the
IS/OS–RPE/T distance returning to WT levels both in superior
and inferior retinal regions treated with subretinal gene therapy
(Fig. 4B, filled symbols) but not in retinal regions away from the
treatment bleb (Fig. 4B, unfilled symbols).
The region of efficacy with subretinal gene therapy is often
shown to extend beyond the bleb formed at the time of the
surgery to include a penumbral region (47, 48). In cBest dogs
with successful gene therapy, there was also a penumbral region
but it appeared to be qualitatively larger than typically encoun-
tered previously (Fig. 4A). In some of the most extreme exam-
ples, pretreatment maps of retina-wide microdetachment were
found to be necessary to demonstrate the extent of penumbral
expansion. EML9-OD, for example, at age 29 wk showed a
retina-wide microdetachment that was most extreme along the
visual streak and included several regions with gross retinal de-
tachments (Fig. 4C). Gene therapy was performed at 69 wk. At
87 wk, microdetachments across the whole retina imaged as well
as the majority of the gross retinal detachments had disappeared
(Fig. 4C), and quantitative measures showed a normal or thinner
IS/OS–RPE/T distance in superior and inferior retinal loca-
tions (Fig. 4D). Importantly, IS/OS–RPE/T distance showed sub-
stantial improvements at retinal locations corresponding to the
bleb formed at the time of the injection as well as in nasal retinal
control regions in the same eye. This extreme example of pen-
umbral expansion is likely explained by greater diffusion of the
vector via the microdetachment in cBest eyes that resulted in the
transduction of the RPE at sites substantially more distant than
the initial bleb. A more typical example with a delimited penumbral
expansion is illustrated for comparison. EML13-OS at age 37 wk
showed microdetachments retina-wide that were especially
prominent in the temporal retina and along the visual streak;
there were also several gross retinal detachments along the visual
streak (Fig. 4E). Gene therapy was performed at 45 wk. At 81 wk
Fig. 3. BEST1 gene augmentation therapy results in sustained reversal
of foveomacular lesions and restoration of RPE–PR interface structure.
(A) Natural history of the central subretinal detachment documented by in
vivo imaging in the right eye of cBest dog (EM356-OD; R25*/P463fs) at three
time points. A series of representative near-infrared reflectance (NIR) images
demonstrate the evolution of the focal lesion (green arrowhead) in the ca-
nine macula from the vitelliform stage (Left) through early pseudohypopyon
(Middle) to an advanced pseudohypopyon stage (Right). (A, Insets) Auto-
fluorescence and OCT images. (B) Subretinal injection with AAV2-cBEST1
(1.5E10 vg/mL) was performed in the eye shown in A at 52 wk of age, en-
tirely encompassing the lesion depicted in the fundus photograph before
injection (b.i.) (Left, Upper Inset). The subretinal bleb area is denoted by the
dashed circle. The treated eye showed ophthalmoscopic resolution of lesion
1 wk postinjection (p.i.) (Left, Lower Inset); however, confirmatory OCT scans
were not available at this age. Images acquired at 43 (Middle) and 245 wk
(Right) p.i. document sustained reversal of the central lesion and fully
reattached retina within the treated area. (B, Middle and Right, Insets)
Autofluorescence and OCT images. EM356-OD and similar labels designate
the individual animal and eye. (Scale bars, 200 μm.) (C and D) Restoration of
RPE–photoreceptor interface structure post AAV-hBEST1 treatment in the
cBest (R25*/R25*) model in comparison with control. (C and D, Upper) NIR
images from EMC3 eyes exhibiting early vitelliform lesions shown at ages 19
(C) and 25 wk (D). Both eyes were injected at 27 wk of age with either BSS (C;
EMC3-OD control eye) or AAV2-hBEST1 (2E11 vg/mL) (D; EMC3-OS study
eye). Bleb boundaries are marked by dashed circles; the locations of corre-
sponding OCT scans cut through the subretinal lesions before injection or
through the matching locations mapped p.i. are marked by green horizontal
lines; retinotomy sites are indicated by blue arrowheads. (Scale bars,
200 μm.) (C and D, Lower) Confocal fluorescence images of IHC assessment of
AAV-hBEST1– or BSS-injected eyes; in contrast to the BSS control eye (C),
cytoskeleton rescue and restoration of RPE–PR interface structure are shown
in AAV-treated retina 103 wk p.i. (D). (Scale bars, 10 μm.)








of age, both superior and inferior retina temporal to the optic
nerve was lacking micro- and macrodetachments, whereas the
untreated nasal retina had retained the microdetachments as
well as formed a large number of macrodetachments (Fig. 4E).
Quantitative results confirmed the treatment effect (Fig. 4F),
which did not reach the nasal retina, unlike EML9-OD.
To understand the potential consequences of gene therapy on
retinal degeneration, ONL thickness was mapped across treated
eyes (Fig. S3B). Treated retinal regions showing disappearance
of microdetachments tended to also correspond to normal ONL
thickness, whereas untreated regions retaining microdetachments
tended to show hyperthick or normal, or in some regions, thinned
ONL (Fig. S3B). In summary, AAV-mediated gene augmentation
therapy in canine bestrophinopathies appears to promote a sus-
tained reversal of gross retinal detachments, reestablishment of a
close contact between RPE and PRs, and return of ONL thickness
to normal values.
Human Autosomal Recessive Bestrophinopathies: Structure and
Function. To facilitate clinical translation of successful gene
therapy in BEST1-mutant dogs, studies were performed to better
understand the human pathophysiology of autosomal recessive
bestrophinopathies (ARBs) and to gain insight into the distribu-
tion of retina-wide disease beyond the gross ophthalmoscopically
detectable lesions previously described. Data are shown (Fig. 5)
from two patients: P1 was a 39-y-old woman with a best corrected
visual acuity of 20/100 carrying biallelic BEST1 mutations
(c.341T>C/c.400C>G), whereas P2 was a 36-y-old man with 20/60
acuity also carrying biallelic mutations (c.95T>C/c.102C>T) in
BEST1. In both patients, mutant alleles segregated with clinically
unaffected parents. Ultrawide imaging of RPE health taking ad-
vantage of the natural autofluorescence of lipofuscin granules they
contain showed widespread and extensive abnormalities consisting
of regions of relative hyper- or hypoautofluorescence and local
heterogeneity. Of note, there was a distinct transition zone (Fig.
5A, arrowheads) in the nasal midperipheral retina demarcating
the healthier nasal peripheral retina.
Rod and cone function was sampled at high density along the
horizontal meridian to better understand the topography of vi-
sion loss and its correspondence to retinal structural abnormal-
ities. Both patients demonstrated a deep (>3 log) loss of rod-
mediated sensitivity centrally in long-term dark-adapted eyes;
there was relative preservation of rod function in the temporal
field (nasal retina) in both patients and the parapapillary area in
one patient (Fig. 5B, Upper). Surprisingly, cone-mediated func-
tion in light-adapted eyes demonstrated only a moderate loss
(<1 log) or normal or near-normal results (Fig. 5B, Lower). Rod
and cone function sampled across the full extent of the visual
field corroborated and extended these findings and showed
strong interocular symmetry (Fig. S7).
Cross-sectional imaging with OCT was performed to evaluate
the retinal lamination abnormalities along the horizontal meridian
Fig. 4. Reversal of microdetachments across retinal
regions after subretinal gene therapy. (A) Pseudo-
color maps of IS/OS–RPE/T distance topography in
cBest-mutant dogs [cmr1 (R25*/R25*), cmr1/cmr3
(R25*/P463fs), or cmr3 (P463fs/P463fs)] subretinally
injected with BSS or AAV-hBEST1. All imaging was
performed in fully light-adapted eyes. Treatment
boundaries are based on fundus photographs of the
bleb taken at the time of the injection (dotted lines)
and, if visible, demarcations apparent at the time of
imaging (dashed lines). All eyes are shown as
equivalent right eyes with optic nerve and major
blood vessels (black), tapetum boundary (yellow),
and fovea-like region (white ellipse) overlaid for
ease of comparison. EML9-OS and similar labels
designate the individual animal and eye. Purple
color depicts gross retinal detachment with an IS/OS–
RPE/T distance of >100 μm. (B) The IS/OS–RPE/T dis-
tance difference from WT at the superior (Left) and
inferior (Right) retinal locations in cBest eyes within
the treated bleb (Tx; filled symbols) and untreated
outside bleb (Ctrl; open symbols) regions. Dashed
lines delimit the 95th percentile of normal variabil-
ity. All AAV-exposed Tx regions are significantly (P <
0.001) different from untreated Ctrl. (C and E) Ex-
amples of eyes where the treatment effect extended
well beyond the initial treatment bleb. Pseudocolor
topographies of the IS/OS–RPE/T distance are shown
pre- (Left) and posttreatment (Right). Purple repre-
sents gross retinal detachments. (C and E, Upper)
Grayscale maps of the difference between each
cBest eye and mean WT control. White represents
gross retinal detachments. (D and F) Measurements
of the colocalized difference of IS/OS–RPE/T distance
between WT and cBest pre- (PreTx) and posttreat-
ment (Tx) for the eyes shown in C and E, respectively.
(D and F, Insets) Locations sampled within (PreTx and
Tx) and outside (Ctrl) the blebs in the superior and
inferior retinas. Note that Ctrl regions in EML9-OD
show a definite treatment effect likely due to the
diffuse microdetachment allowing for widespread
vector-driven transduction.
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crossing the fovea (Fig. 5C). There was not a consistent light-
exposure history at the time of OCT imaging. Both patients
showed a significant loss of ONL and abnormalities at the level
of photoreceptor IS/OS in the outer retina across most of the
central retina. P2, in addition, showed intraretinal cystic spaces
and the detachment of the central retina from the RPE, likely
due to accumulation of subretinal fluid. The retinal lamination
showed relative normalization in the parapapillary region (Fig.
5C, red rectangles) and beyond the nasal midperipheral transi-
tion (Fig. 5C, green rectangles). Analyses of the two regions of
interest showed detectable but abnormally thinned ONL, and
detectable IS/OS and cone outer segment tip (COST) with low
peak signal in both patients (Fig. 5 D and E). In P1, the distances
from the ELM to IS/OS and IS/OS to COST were comparable to
normal. There appeared to be a hyposcattering layer distal to
COST, and the RPE appeared hyperthick (Fig. 5D, Middle). In
P2, ELM to IS/OS appeared shorter than normal, whereas
IS/OS-to-COST distance was comparable to normal. COST-
to-ROST/RPE distance appeared greater than normal with an
intervening indistinct hyposcattering layer; the RPE appeared to
be comparable in thickness to normal (Fig. 5D, Right). Analysis of
the outer retina in the nasal midperipheral region in P1 showed
ELM-to-IS/OS, IS/OS-to-COST, and COST-to-ROST/RPE dis-
tances greater than normal and RPE thickness which was compa-
rable to normal (Fig. 5E,Middle). P2 features appeared intermediate
between P1 and normal (Fig. 5E, Right).
To understand the implications of structural abnormalities at
the level of the outer retina and RPE for the kinetics of retinoid
transfer between these cellular layers, dark-adaptation testing
was performed. At the parapapillary location shown in Fig. 5D,
dark-adapted thresholds of P1 were rod-mediated but 1.3 log
unit-elevated (Fig. 5F). By 22.5 min following a light exposure,
the P1 results had remained cone-mediated on a plateau whereas
normal was already within 1 log unit of the final dark-adapted
threshold. By 50 min, P1 rod results were still 1 log-elevated
whereas normal recovery was complete (Fig. 5F). At the mid-
peripheral nasal retinal location shown in Fig. 5E, dark-adapted
thresholds of P2 were rod-mediated and ∼0.5 log unit-elevated
compared with normal (Fig. 5G). By 14.5 min following a light
exposure, there was first evidence of rod function which was only
incrementally slower than the 11-min cone–rod break in normal.
The rate of rod recovery was similar to normal (Fig. 5G). In
summary, rod dark-adaptation kinetics of P1 at the parapapillary
locus showed an extremely slow time course, whereas dark-
adaptation kinetics of rod function of P2 at the midperipheral
locus was closer to normal (Fig. 5 F and G).
Discussion
The RPE has a key role in maintaining the metabolically active
environment of the subretinal space (25, 26, 49). Due to the
dynamic relationship with adjacent retinal layers, mutations in
RPE-specific genes often adversely affect the neighboring sen-
sory neurons, leading to loss of visual function and PR de-
generation (50–52). Mutations in BEST1 are known to disrupt
transepithelial ion and fluid transport in response to abnormal
levels of intracellular calcium (11–13). Abnormal RPE calcium
signaling is also thought to lead to dysregulation of other pathways
through altered expression and interactions of Ca2+-sensitive
proteins (20, 53). Based on our findings in cBest, one such protein
is EZRIN, a membrane–cytoskeleton linker essential for the
formation and proper maturation of RPE apical MV (54–57). It
has been demonstrated that the activation of EZRIN’s mem-
brane–F-actin cross-linking function occurs directly in response
to Ca2+ transients (55), and Ezrin-KO mice exhibit a substantial
decrease in elaboration of RPE MV (57). The apparent under-
development of RPE apical MV found in the BEST1-mutant
RPE is consistent with these reports. Furthermore, our com-
parative IHC assessments with other IRD models demonstrated
that these major structural alterations associated with microvillar
ensheathment are specific to the primary RPE channelopathy
triggered by BEST1 mutations, and not secondary to cone dys-
function and degeneration.
The structural components of RPE apical processes are very
different from those of nonmotile intestinal microvilli (57–59).
The presence of contractile proteins (such as myosin) in the RPE
apical microvilli, and also molecules typically found at the sites of
Fig. 5. Retinotopic phenotype in patients with ARB. (A) RPE health across the
retinas of two ARB patients, P1 and P2, imaged with short-wavelength
reduced-illuminance autofluorescence imaging (SW-RAFI), taking advantage
of the natural RPE fluorophore lipofuscin. White arrows depict the location of
the perimetric profiles and OCT scans; red and green rectangles show the re-
gions of interest shown in other panels; and black arrowheads demarcate
disease-to-health transition in the nasal midperipheral retina. (A, Inset) Normal
SW-RAFI for reference. (B) Perimetric light sensitivity of rods in dark-adapted
(Upper) and cones in light-adapted (Lower) eyes measured across the hori-
zontal meridian. Gray regions represent normal sensitivity except for the
physiological blindspot corresponding to the optic nerve (ONH). (C) Retinal
cross-section with OCT along the horizontal meridian crossing the fovea. (C,
Inset) Normal OCT for reference. (D and E) Detail of outer retinal lamination
in patients compared with normal at the two regions of interest at the par-
apapillary retina (D, red) and midperipheral nasal retina (E, green). Layers and
peaks are highlighted for visibility. Orange indicates interface near COS tips,
blue indicates interface near ROS tips and RPE apical processes, brick indicates
interface near the RPE and Bruch’s membrane. (F and G) Dark-adaptation
kinetics measured in P1 at the parapapillary locus (F) and in P2 at the nasal
midperipheral locus (G). Time 0 refers to the end of adaptation light. Baseline
thresholds obtained after extended dark adaptation are shown before time 0.








cell attachments, suggests that the RPE actively adheres to, and
exerts tension on, the neural retina (58, 59). The dearth of a
proper microvillar ensheathment at the RPE–PR interface in
cBest, and thus an absence of physical and electrostatic support
by these projections to the PR OS, would be expected to weaken
the adhesive forces and lead to separation of the RPE–PR
complex retina-wide. The microdetachment of the PR layer from
the underlying RPE found in cBest at the earliest stages of dis-
ease would be consistent with this process. Moreover, the pres-
ence of contractile elements in the RPE apical projections and
the fact that they have evolved from cells in which pigment mi-
gration occurred (58) indicate that MV are capable of active
contraction while interdigitating with PR OS, and are destined to
facilitate circadian phagocytic activity. A single RPE cell can
accommodate about 30 to 50 PRs, depending on the retinal lo-
cation and packing density (60, 61); the elaborate network of
microvilli allows each RPE cell to handle such a high metabolic
load on a daily basis. Insights from proteomic profiling support
this argument. There is an enriched fraction of retinoid-
processing proteins expressed along the RPE apical MV, to-
gether with a number of channel proteins and transporters (i.e.,
Na+/K+ ATPase) central to the efficient transport of water, ions,
and metabolites between the RPE and PR OS (26, 59). Con-
sidering the topographic differences in the size of RPE cells and
taking into account the density and length of MV quantified in
this study, MV extensions expand the functional surface of a
single RPE cell by 20- to 30-fold in the central retina, which is
consistent with earlier estimates (62). This number is even higher
(∼50-fold) for the small RPE cells in the macular region (26, 61,
63) that adapted to a higher turnover rate of shed POS while
facing the most densely packed PRs. Such dramatic reduction in
a total apical surface area in BEST1-mutant RPE will lead to a
chronic delay in processing of metabolites, and arrest the abil-
ities of the RPE to maintain both the proper cell volume as well
as chemical composition and physiological pH levels in the
subretinal space. Since these factors are essential for retinal
adhesion (26), any limitation in the RPE transporting system will
alter the balance of hydrostatic forces and result in decreased
osmoelastic properties of the RPE–PR complex with subsequent
separation from the neuroretina. Indeed, the primary serous
detachment in human and canine bestrophinopathy is first evi-
dent in the fovea, the central area of highest metabolic activity.
The absence of high-reaching RPE apical processes, which in the
structurally intact retina tightly wrap COS up to the ellipsoids
(64), would explain the predilection of this cone-rich structure
for its primary detachment in bestrophinopathies. There would
be almost exclusive reliance on the frictional interactions with
the MV. This is consistent with our observations in cBest, doc-
umenting formation of the focal previtelliform lesions within the
canine fovea-like area of the area centralis, and also the sus-
ceptibility of other central cone-rich areas (like visual streak) to
subretinal detachment.
Less expected was the major expansion of microdetachments
in cBest upon exposure to dim and moderate light intensities. In
normal eyes, light exposure is known to change molecular
composition of the subretinal space (65). There is also evidence
that measurable structural changes occur in the normal outer
retina with light exposure, such as changes in outer segment
length (39, 40, 66, 67), hydration of the subretinal space (27–29,
35, 68), increased actin staining along RPE apical MV (37), and
phototropism of outer segments (69). However, all of the normal
changes are substantially smaller than those measured in cBest.
For example, normal human eyes showed changes of ∼1 μm (40),
and normal mouse eyes showed changes of ∼4 μm in the outer
retina (37), compared with ∼18-μm expansion of the subretinal
space driven by light in cBest. Human ARB has only recently
been recognized and the literature on the earliest disease stages
is limited. Specifically, we are not aware of any ARB literature
that has performed quantitative measurements of the outer
retina. The recessive cBest disease appears to have phenotypic
similarities to both dominant and recessive bestrophinopathies in
humans. In patients with dominant BEST1 disease (BVMD),
there has been some controversy regarding the structural fea-
tures of retinal regions surrounding vitelliform or later-stage
lesions, or retinas in the previtelliform stage of disease. Some
studies have demonstrated minor abnormalities at the level of
the RPE–PR interface (34, 70, 71), whereas results from others
support no detectable structural defects (72–74). Contributing to
this controversy could be genotype (75), the resolution of dif-
ferent methodological approaches used, or light history pre-
ceding the imaging (36). Indeed, light-dependent outer retinal
changes have been described in BVMD using methods like those
reported here (36); still, the magnitude of the changes reported
in patients was smaller (∼2 μm) than in cBest. In general, how-
ever, the abnormal response of the affected retina to light stimuli
could be related to the markedly reduced light peak/dark trough
ratio in the electrooculogram, a finding consistent in all, even
presymptomatic, BEST1 patients.
Of importance, both the micro- and macrodetachments in cBest
had adverse effects on photoreceptor health: Regions of micro-
detachment tended to correspond to hyperthick ONL, whereas
large lesions with gross macrodetachment showed thinning of
ONL. Smaller lesions with macrodetachment could not be
assessed with the sampling methods used here. ONL contains the
nuclei of all rods and cones, and classic studies in animal models
and human eye donors have generally shown thinning of the ONL
with disease progression (76, 77). Less well known are some of the
earliest stages of retinal disease showing ONL thickening, which
has only become measurable with the advancement of in vivo
imaging methods. Human studies have previously demonstrated
such ONL thickening in early stages of retinal diseases (78–81).
There has also been evidence in animal studies of ONL thickening
associated with retinal stress (82). The hyperthick regions of ONL
mapped in cBest when examined microscopically showed the
number of PR nuclei to be comparable to control, suggesting a
greater internuclear spacing within the ONL, likely corresponding
to a level of retinal stress that is below the apoptosis threshold.
Gross retinal detachments, on the other hand, may cause greater
retinal stress and progressive degeneration (17, 83).
To prevent the photoreceptor and vision loss associated with
BEST1 mutations, we performed subretinal gene augmentation
therapy directed to retinal areas with macro- and microdetach-
ments. Our results showed that AAV-mediated BEST1 gene
augmentation is safe, reverses the clinically obvious lesions,
ameliorates the diffuse microdetachments, and results in nor-
malization of hyperthick ONL. Furthermore, we demonstrated
gene therapy success in three distinct BEST1 genotypes with
both focal and multifocal presentations, and confirmed long-
term durability of the treatment effect. At the molecular level,
we confirmed that both the canine as well as the human BEST1
transgene can correct the apposition of the RPE–PR complex
and restore the cytoarchitecture of this critical interface. Our
study suggests that early as well as more advanced stages of
autosomal recessive disease are sensible to approach with this
therapy. Further studies utilizing human inducible pluripotent
stem cell (hiPSC)-derived RPE models derived from patients
harboring autosomal dominant BEST1 mutations (17, 53) will
determine whether the gene augmentation approach would also
be beneficial for BVMD patients.
To facilitate the clinical translation of successful gene aug-
mentation therapy, ARB patients were studied to gain insight
into their retina-wide disease. Consistent with most, but not all,
previous descriptions (84–88), retinal disease in our ARB pa-
tients extended well beyond the macula into the midperiphery.
Our retinotopic mapping of en face and cross-sectional imaging
and rod and cone function demonstrated the existence of a
distinct transition from disease to health in the midperipheral
retina, a feature not previously emphasized. Within the diseased
region, severe abnormalities in retinal structure were associated
with severe loss of rod function; unexpectedly, cone function was
relatively retained. Rod dysfunction within the central retina
was also associated with extreme slowing of the retinoid cycle,
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whereas the healthier periphery showed near-normal recycling of
the retinoids. There are at least two retinoid cycles that provide
the 11-cis-retinal chromophore to photoreceptor pigments. The
canonical retinoid cycle functions in the RPE to produce chro-
mophore for rod and cone PRs (89). The retinal retinoid cycle,
on the other hand, is thought to regenerate chromophore within
the retina for the specific use of cones (90, 91). The abnormal
RPE–PR interface in BEST1 disease would most likely affect the
chromophore delivery from the canonical RPE retinoid cycle;
the retinal retinoid cycle may be relatively unaffected, thus
explaining the greater retention of cone function.
In summary, our study uncovered new molecular contributors
to the pathophysiology of bestrophinopathies at the RPE–PR
interface. We discovered the earliest expression of disease: a
diffuse microdetachment potentiated by light exposure that was
easily detectable by in vivo imaging. We showed that AAV-
mediated BEST1 augmentation gene therapy reverses both the
grossly obvious lesions and microdetachments, and restores the
cytoarchitecture of the RPE–PR interface. Evaluation of ARB
patients showed retinotopic distribution and properties of
structural and functional defects beyond that expected from PR
degeneration. Such visual dysfunction may be expected to im-
prove upon successful application of BEST1 gene augmentation
therapy to patients affected with bestrophinopathies.
Materials and Methods
Human Subjects. Two unrelated patients with ARB were included. Proce-
dures followed the Declaration of Helsinki guidelines. Informed consent
was obtained, and all procedures were approved by the Institutional Re-
view Board of the University of Pennsylvania. Patients underwent a com-
plete eye examination and ancillary tests as previously described (92–95).
Further experimental details are described in SI Materials and Methods.
Canine BEST1 Models and in Vivo Retinal Imaging. cBest-mutant dogs (n = 18)
of both sexes (12 M and 6 F) harboring either homozygous (c.73C>T)
(p.R25*/R25*) or (c.1388delC) (p.P463fs/P463fs) or biallelic (c.73C>T/1388delC)
(p.R25*/P463fs) mutations in cBEST1 (GB*NM_001097545) were included. For
ease of annotating the multipanel figures, the three genotypes, respectively,
are referred to as cmr1, cmr3, and cmr1/cmr3. The study was conducted in
comparison with control cross-bred dogs (n = 12; 7 M and 5 F) (Table S1). All
animals were bred and maintained at the Retinal Disease Studies Facility
(RDSF). The studies were carried out in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory Animals of the
NIH (96) and in compliance with the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision
Research. The protocols were approved by the Institutional Animal Care and
Use Committee of the University of Pennsylvania (IACUC nos. 804956 and
803422). En face and retinal cross-sectional imaging was performed with the
dogs under general anesthesia as previously described (24, 97). Further
methodological details are provided in SI Materials and Methods.
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